Healthcare Brew’s Post

Below is our agenda and meeting info for this Thursday's DIA RIM Working Group All Hands meeting at noon ET. Hope you can join us. - Working group sub-team updates - FHIR discussion: Please come ready to share what your firm is doing to be ready to use FHIR for submitting data to agencies and bring your questions. - Charter review and future topic planning (time permitting) DIA members can join here: RIM Working Group All-Hands Meeting - Drug Information Association (diaglobal.org) #rim #diarim #regulatory #fhir #pharma #lifescience

Important piece by our WHIC partner Matt Wetzel and his colleagues at Goodwin: Summary: "Anticipated changes span multiple regulatory fronts: a revamped approach to antitrust review at the Federal Trade Commission (FTC), continued momentum on biosecurity measures, and a fundamental rethinking of agency regulation to streamline “red tape” and accelerate patient access to innovative treatments. The Trump administration’s stated focus on “making America healthy again” suggests a broader transformation in how healthcare is delivered and regulated, with emphasis on nutrition, prevention, longevity, enhanced physician autonomy, and a more holistic approach to health to reduce the burdens of chronic disease." https://lnkd.in/eA2C5VgY

West's global study on patients and health care professionals perspectives on self-administration, highlighted differences in prescribers experiences and the age the of a patient when it comes to preference of self-administration. Learn more: https://bit.ly/3SMlEsF

PHYSICIANS CALL FOR A HEALTH-FIRST APPROACH TO DRUG POLICY IN NEW POSITION STATEMENT Timed with the NSW Drug Summit, our new position statement focuses on the need to have a comprehensive approach to drug policy that is evidence-based and includes education, harm prevention and reduction, and treatment. “Government needs to address drug use from all angles – there is no one silver bullet that will fix the issue because as physicians, we know that a health-focused approach requires a comprehensive understanding of interconnecting issues" says RACP President, Professor Jennifer Martin. Read our position statement to find out more. https://lnkd.in/gq5TBQaZ

West's global study on patients and health care professionals perspectives on self-administration, highlighted differences in prescribers experiences and the age the of a patient when it comes to preference of self-administration. Learn more: https://bit.ly/3SMlEsF

The opioid crisis demands solutions that are both precise and impactful. QuidelOrtho is stepping up with a fentanyl detection solution that equips healthcare providers with the tools to save lives and respond to this growing challenge. In a recent CLINICAL24 interview with SelectScience, our own Andrew Corkum, senior vice president, head of EMEA and LATAM, shared how our innovation is making a real-world impact. Discover how we're transforming healthcare to support communities. Watch the full interview here: https://lnkd.in/gV7SZzgv. #OpioidCrisis #FentanylDetection #DiagnosticsThatDeliver #HealthcareInnovation

West's global study on patients and health care professionals' perspectives on self-administration, highlighted differences in prescribers experiences and the age the of a patient when it comes to preference of self-administration. Learn more: https://bit.ly/3SMlEsF

Austria: Vascular Stress Markers Following Inhalation of Heated Tobacco Products: A Study on Extracellular Vesicles “Our findings reveal a significant increase in EVs of endothelial and platelet origin following short-term HTP inhalation with nicotine. Notably, no significant change was observed in leukocyte- and neutrophil-derived EVs. This increase in EVs suggests acute vascular stress, with peak levels observed 4 h post-exposure. The rise in endothelial and platelet-derived EVs aligns with documented responses to acute vascular injury, paralleling the effects seen with traditional cigarette and e-cigarette use. Despite HTPs being marketed as safer alternatives, our results indicate that nicotine-containing HTPs may still pose significant vascular risks. These findings contribute to the growing body of evidence cautioning against the perceived safety of HTPs and reinforce the importance of regulatory oversight and public health initiatives targeting nicotine delivery technologies. Trial Registrations: ClinicalTrials.gov ID: NCT04824495, registered 2021–01-07.” https://lnkd.in/ghKfkUCj

The FDA's confusing wording surrounding the relabeling of transmucosal buprenorphine products has caused some uncertainty in the medical community. The agency's guidance appears unclear about whether the relabeling requirements apply to all buprenorphine formulations or only specific ones, such as those intended for opioid use disorder treatment. This lack of clarity has led to challenges for healthcare providers in ensuring compliance with updated regulations and properly communicating the potential risks and benefits of these medications to patients. Clearer, more precise language from the FDA would help mitigate confusion and improve the effective use of buprenorphine in clinical practice. Do you agree?

For our DIA RIM #intelligentautomation (IA) meeting on Wednesday at 11am ET, we will be reviewing the draft IA survey to obtain your feedback on the questions. Here's the members-only meeting link for Wednesday. Hope to see you there! RIM Intelligent Automation Team Meeting - Drug Information Association (diaglobal.org) #diarim #rim #ai #genai #regulatory #pharma